Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD7 CAR-T for R/R T-ALL/Lymphoma
NCT05212584Phase 1Unknown
- Sponsor
- iCell Gene Therapeutics
- Start
- Jul 2022
- Primary completion
- Jun 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UTAA07 in t-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma, sponsored by iCell Gene Therapeutics. Primary endpoint: Number and incidence of adverse events at 3 months. Status: unknown.
02
Drugs
UTAA07
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T-cell lymphoma
Beyond the preview
Go deeper on NCT05212584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05212584.